STAT News · Scour

STAT+: Vertex says its drug successfully reduced marker of kidney disease in late-stage trial

statnews.com·9w

STAT+: The ER staffing conflict, and no facility fee for a marmot

statnews.com·9w

STAT+: A setback for Roche’s breast cancer drug

statnews.com·9w

STAT+: Novo Nordisk, Hims reach deal to end bitter dispute over Wegovy sales

statnews.com·9w

Fresh turmoil at the FDA with Prasad’s exit

statnews.com·9w

STAT+: Pharmalot: We’re reading about a lack of FDA adcomms, FDA loosening biosimilar rules, and more

statnews.com·9w

STAT+: Talkspace to be acquired for $835 million by mental health services giant

statnews.com·9w

STAT+: Xenon Pharmaceuticals’ seizure drug shows strong efficacy in late-stage trial

statnews.com·9w

STAT+: As controversial decisions mount, FDA shuns public advisory meetings

statnews.com·9w

STAT+: Blue Cross Blue Shield says data back up claim that AI is driving up medical bills

statnews.com·9w

STAT+: Health tech company says it will dive into Medicare’s new chronic care experiment

statnews.com·9w

STAT+: After UnitedHealth moved in, Oregon sought to rein in corporate health care. Now, it’s facing an early test

statnews.com·9w

Opinion: America must not learn to live with 72,000 overdose deaths a year

statnews.com·9w

Opinion: The financial reason why parents beg me to diagnose their kids with autism

statnews.com·9w

STAT+: 5 lessons from Vinay Prasad’s turbulent tenure at the FDA

statnews.com·9w

Federal autism advisory board cancels first public meeting since 2024

statnews.com·9w

Vinay Prasad, key Makary ally and a focus of controversy at the FDA, is leaving the agency

statnews.com·10w

STAT+: Novo Nordisk’s Wegovy and Ozempic shots could be made for as little as $3 a month, analysis finds

statnews.com·10w

STAT+: Up and down the ladder: The latest comings and goings

statnews.com·10w

The FDA, urged to avoid controversy, creates a new headache with attack against UniQure

statnews.com·10w

Log in to enable infinite scrolling